All News
Filter News
Found 142 articles
-
Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer
10/19/2021
Artizan Biosciences, Inc., a biotechnology company at the frontier of microbiome precision medicine, announced the appointment of Bridget Martell, M.A., M.D., as President and Chief Executive Officer.
-
Pathogens for antimicrobial resistance may still be a bit off peoples’ radar, but the lessons from unpreparedness of COVID-19 are in the mind of Qpex.
-
Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease
10/8/2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced the filing of an emergency use authorization (EUA) application for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII-196/BRII-198.
-
Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
10/4/2021
Brii Biosciences Limited presented at IDWeek 2021 interim results from Phase 3 of the ACTIV-2 trial, which showed that BRII-196/BRII-198, the Company's neutralizing monoclonal antibody combination therapy for SARS-CoV-2, achieved a similar reduction in hospitalization or death among patients who initiated treatment early versus late following symptom onset.
-
Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy
9/28/2021
Strategic senior hire strengthens Brii Bio' leadership team and positions the Company for U.S. market access and commercialization
-
Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
9/7/2021
Brii Biosciences Limited a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, announced that the Company is committing an additional US$100 million to advance global regulatory filings and commercial efforts for its investigational SARS-CoV-2 combination therapy, BRII-196/BRII-198.
-
Clinical Catch-Up: August 23-27
8/30/2021
It was a busy week for clinical trial news. Here’s a look. -
Early data from a Phase III study for COVID-19 shows significant promise with its combo therapy reduced death and hospitalization in trial patients at high risk of progression by 78%.
-
Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
8/24/2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) , today announced that its SARS-CoV-2 (virus that causes COVID-19) neutralizing monoclonal antibody combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198"),
-
Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19
8/5/2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical need and large public health burden, today announced that the Phase 3 portion of the ACTIV-2 study evaluating its monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198
-
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
8/5/2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.
-
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
6/25/2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection.
-
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
6/23/2021
Brii Biosciences today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection.
-
Qpex Biopharma Initiates Phase 1 Study of QPX9003 Targeting Antibiotic-Resistant Pathogens
6/17/2021
Qpex Biopharma, Inc. announced initiation of a Phase 1 study of QPX9003, a next generation intravenous (IV)-administered synthetic polymyxin for infections.
-
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021
6/9/2021
VBI Vaccines Inc. today announced that two abstracts featuring data from the Company’s prophylactic and therapeutic hepatitis B (HBV) candidates have been accepted for presentation at The Digital International Liver Congress™ 2021.
-
Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
6/9/2021
Brii Biosciences today announced that it will present at the European Association for the Study of the Liver’s (EASL) International Liver Congress 2021, which is taking place virtually from June 23-26, 2021.
-
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
-
Brii Biosciences Provides Update on Strategic Clinical Development Progress
5/17/2021
Company received U.S. FDA clearance of Investigational New Drug Applications for four diverse pipeline candidates and advanced each into the clinic.
-
Qpex Biopharma Initiates Phase 1 Study of ORAvance™ for Oral Treatment of Drug-Resistant Gram-Negative Bacterial Infections
5/12/2021
Qpex Biopharma Initiates Phase 1 Study of ORAvance ™ for Oral Treatment of Drug-Resistant Gram-Negative Bacterial Infections